Strategy& Middle East: GCC healthcare sector could save US$2.5bln by investing in workforce wellbeing

Prioritizing healthcare workforce wellbeing results in 17% reduction in absenteeism, 11% decrease in staff turnover, 25% increase in productivity
Dubai, UAE: New research by Strategy& Middle East, part of the PwC network, estimates that investing in workforce wellbeing could generate savings of as much as US$2.5 billion in the GCC healthcare sector. The findings highlight the unique set of challenges affecting healthcare workers' physical and mental wellbeing and illustrates how investment in workforce wellbeing could have a significant impact.
Long hours, high-intensity work environments, and physically demanding tasks contribute to chronic fatigue and other health problems. According to reports, almost 50% of healthcare professionals worldwide are affected by burnout, while nearly 48% globally suffer from musculoskeletal issues each year. With the GCC healthcare sector workforce comprising more than 800,000 workers in 2025, investment in strengthening workplace wellbeing has the potential to create significant impact across the sector.
The human cost
Recent studies indicate that healthcare burnout contributes to a fourfold decrease in job satisfaction, while doctors experiencing burnout are 2.2 times more likely to have made a medical error in the past three months. Additionally, the emotional toll of patient suffering, navigating difficult diagnoses, and making life-or-death decisions take an emotional toll. As these challenges mount, healthcare systems become increasingly stretched, with workforce shortages compounding existing pressures.
'With the GCC healthcare sector undergoing rapid transformation and a sizable workforce already employed in the industry, prioritizing workforce wellbeing is more critical than ever. Beyond benefiting employees, efforts in this area could deliver clear financial gains and drive broader improvements across the sector, enhancing overall system performance,' said Irfan Merali, Partner at Strategy& Middle East.
The business impact
The impact on personal wellbeing also extends to financial and systemic repercussions, with poor wellbeing driving absenteeism, staff turnover, and declining job satisfaction, creating a vicious cycle that harms both healthcare workers and patients. Research shows that prioritizing workforce wellbeing leads to an increase of up to 25% in productivity, a 17% reduction in absenteeism and an 11% decrease in staff turnover. This also includes an overall impact on the sector including higher job satisfaction, fewer medical errors, and enhanced patient outcomes – and a system-wide potential saving of US$ 2.5 billion in the GCC.
Adopting a pro-active approach
The research suggests healthcare providers adopt a structured approach that combines preventative and intervention strategies to help drive improvements:
Primary interventions, which aim to eliminate or mitigate workplace stressors at their source, could help to foster long-term improvements over temporary morale boosts. By assessing the work environment, organizational practices, and job roles, healthcare institutions can tackle issues such as excessive workloads, rigid shifts, and role ambiguity.
Secondary interventions, focus on empowering healthcare workers with the skills and strategies to cope with stressors that cannot be avoided or eliminated, such as high patient volumes, ethical dilemmas, and emotional strain. This can be achieved through resilience training, stress management workshops, mindfulness programs, and peer support networks to help employees navigate high-pressure situations effectively.
Tertiary interventions, designed to assist healthcare professionals already experiencing significant stress-related symptoms can ensure they receive the support needed to recover and reintegrate effectively. Access to counseling, physiotherapy and employee assistance programs can help professionals recover, reduce the risk of physical strain and chronic musculoskeletal conditions, as well as return to optimal functioning. Given that healthcare organizations already provide similar services to patients, there is an opportunity to extend these resources to employees in a cost-effective and sustainable manner.
'A resilient healthcare system depends on healthy, supported professionals who can meet evolving demands. Investing in workforce wellbeing isn't just the right thing to do; it is essential to create a resilient system that enables better outcomes for all. By prioritizing their wellbeing, the sector ensures long-term quality, efficiency, and sustainability of the entire healthcare system," said Dr. Christelle Abou Nader, Manager at Strategy& Middle East.
About Strategy&
Strategy& is a global strategy consulting business uniquely positioned to help deliver your best future: one that is built on differentiation from the inside out and tailored exactly to you. As part of PwC, we're building the winning systems that are at the heart of growth every day. We combine our powerful foresight with this tangible know-how, technology, and scale to help you create a better, more transformative strategy from day one.
As the only at-scale strategy business that's part of a global professional services network, we embed our strategy capabilities with frontline teams across PwC to show you where you need to go, the choices you'll need to make to get there, and how to get it right.
The result is an authentic strategy process powerful enough to capture possibility while pragmatic enough to ensure effective delivery. It's the strategy that gets an organization through today's changes and drives results that redefine tomorrow. It's the strategy that turns vision into reality. It's strategy, made real.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Zawya

3 hours ago

• Zawya

WCM-Q concludes 2025 cycle of biomedical research training program

Doha – Four aspiring biomedical scientists have gained key research skills by completing the 2025 cycle of Weill Cornell Medicine-Qatar's (WCM-Q) Biomedical Research Training Program (BRTP) for Nationals. The interns who participated in this year's program are Raghad Rabie El Ghali, Hadeel Alashwal, Maryam Ali, and Sara Muhamed Saleh. The program is designed to give Qatari nationals and long-term residents who have recently graduated from college a firm foundation in practical laboratory and research administration skills, and experience conducting real clinical research projects while working alongside WCM-Q's highly qualified scientific faculty in the college's state-of-the-art laboratories. To celebrate their successful completion of the program, the interns were presented with certificates at a special graduation ceremony. This year marks the 13th annual cycle of the Biomedical Research Training Program for Nationals, which was launched in 2011. To date, the program has helped 62 graduates, including this year's cohort, take their first steps toward successful careers in research. Dr. Khaled Machaca, professor of physiology and biophysics/senior associate dean for research, innovations, and commercialization at WCM-Q, said: 'I am honored to congratulate our latest cohort of talented graduates from the Biomedical Research Training Program. These impressive young scientists have dedicated the last 10 months to acquiring the skills and knowledge needed to become not only exceptional scientists but also vital contributors to Qatar's thriving biomedical research sector. I wish them every success in the next stages of their careers.' This year's BRTP interns are graduates of Hamad Bin Khalifa University, Qatar University, the University of Zhengzhou in China, and the International Medical University in Malaysia. Tembela Eweje, associate director, grants, contracts and research training, said: 'This program is more than just training; it's about building a diverse and capable biomedical workforce for Qatar. The program is designed to equip emerging scientists with critical skills and provide the mentorship they need for their careers after completion. During the graduation ceremony, our trainees expressed their excitement about the future and their eagerness to engage in activities that will help them gain the expertise needed to lead transformative research. One trainee mentioned that the program provided them with what they would equate to about 10 years of experience in just 10 months.' The program has become an established bridge for college graduates to transition to the workplace and kickstart successful careers in research. Graduates from previous cycles have gone on to publish in leading journals and have been accepted to graduate school programs in Qatar and abroad, while others have established careers in research at prestigious institutions across Qatar and the region. About Weill Cornell Medicine-Qatar Weill Cornell Medicine-Qatar is a partnership between Cornell University and Qatar Foundation. It offers a comprehensive Six-Year Medical Program leading to the Cornell University M.D. degree with teaching by Cornell and Weill Cornell faculty and by physicians at Hamad Medical Corporation (HMC), Sidra Medicine, the Primary Health Care Corporation, and Aspetar Orthopedic and Sports Medicine Hospital, who hold Weill Cornell appointments. Through its biomedical research program, WCM-Q is building a sustainable research community in Qatar while advancing basic science and clinical research. Through its medical college, WCM-Q seeks to provide the finest education possible for medical students, to improve health care both now and for future generations, and to provide high quality health care to the Qatari population. For more info, please contact: Hanan Lakkis Associate Director, Media and Publications Weill Cornell Medicine - Qatar hyl2004@

Khaleej Times

10 hours ago

• Khaleej Times

UAE evacuates 3-year-old Palestinian child suffering from burns, orphaned after airstrike

A critically injured Palestinian child from Gaza has been medically evacuated to the UAE for advanced treatment after sustaining second- and third-degree burns across multiple areas of his body, as part of the UAE's ongoing humanitarian mission 'Operation Chivalrous Knight 3'. Three-year-old Hatim Awad suffered the injuries during an airstrike that struck his neighbourhood in Gaza. Tragically, the attack also claimed the lives of his entire family, leaving the child to battle both physical and emotional trauma alone, an ordeal reflecting the suffering of thousands of children in Gaza Strip. The child arrived at the hospital on June 12, Dr Abdulqader Almessabi, Chief Medical Officer at Sheikh Shakhbout Medical City, confirmed. He stated that a comprehensive treatment plan was promptly implemented, and the child has shown significant improvement since beginning care. The evacuation was carried out in coordination with the relevant authorities to ensure the child's safety throughout the journey and during his transfer to Sheikh Shakhbout Medical City for specialised care. Watch a video, shared by Wam, here: The urgent evacuation underscores the UAE's continued efforts to alleviate the humanitarian crisis in Gaza, with a focus on providing medical and relief support to the most vulnerable, especially children and patients.

Arabian Post

11 hours ago

• Arabian Post

AI‑Powered Phage Therapy Set to Tackle Antibiotic Resistance

Phagos, a Paris‑based biotech startup, is deploying an artificial‑intelligence model built on Amazon Web Services to accurately match bacteriophages with antibiotic‑resistant bacterial strains. This development marks a pivotal shift from arbitrary trial‑and‑error methods to precision medicine in combating infections that claim an estimated one million lives annually. The challenge of antibiotic resistance has spurred Phagos, co‑founded by microbiologist Adèle James and economist Alexandros Pantalis, to pursue alternative therapies. Phages are viruses that specifically infect bacteria, a property that enables targeted treatment without disrupting beneficial microorganisms. But identifying the right phage for a given pathogen has traditionally required labour‑intensive screening of millions of combinations. Phagos is leveraging AWS's Generative AI Accelerator Programme, which has provided them with cloud credits, embedded AWS architects and machine‑learning engineers, and dedicated mentorship, to build a generative AI platform capable of predicting effective pairings between phages and bacterial strains. The AI model has been trained on datasets from public repositories and proprietary lab results. ADVERTISEMENT 'We can now read into the DNA and see if there's going to be an interaction between a phage and a bacterium,' Pantalis explained. This capability bypasses exhaustive wet‑lab testing and accelerates the discovery pipeline. Phagos's strategy involves initial trials in animal health—shrimp, chicken, bovine, swine—with phages administered through water systems to curb infections in farm environments. James noted that reducing antibiotic use in livestock is critical, as drug‑resistant bacteria generated in farms can transfer to humans via environmental pathways. The startup's first validation came from a collaboration with an oyster farmer in France, where AI‑matched phages slashed mortality by 40 per cent. Technical infrastructure from AWS played a crucial role, with cloud experts helping to refine the system and scale it efficiently. 'We became much faster, and spent way less time figuring out how to set up our infrastructure,' James said. Globally, the antibiotic resistance crisis is projected to cause more deaths than cancer by mid‑century, with economic impacts exceeding US$1.5 trillion. By automating phage matching, Phagos aims to create personalised and adaptive therapies that evolve in tandem with bacterial mutations. Participation in AWS's 2024 accelerator—which selected just 80 startups from over 4,700 applicants—has provided Phagos not only with technical and financial support, but also exposure to industry networks and potential funding sources. The platform-as‑a‑service model being developed by Phagos positions the company as a pioneer in AI‑driven microbiological model building. One quarter of its team now focuses exclusively on data and machine learning, a rarity in biotech. Expansion plans are underway: the company intends to move into human therapeutic applications by 2030, while continuing its work in agriculture. It is also advancing bespoke phage therapies, distinguishing itself from generic phage cocktails pursued by competitors. While obstacles remain—such as regulatory pathways for phage-based treatments and the complexity of bacterial ecosystems—Phagos believes its AI model and cloud infrastructure provide a scalable solution. Each new phage cocktail generates data that feeds into the platform, enhancing future predictions.